- Molecular NameDrospirenone
- Synonym6β,7β,15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17 carbolactone; Drospirenona [inn-spanish]; Drospirenonum [inn-latin]; DRSP
- Weight366.501
- Drugbank_IDDB01395
- ACS_NO67392-87-4
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)3.09
- pkaN/A
- LogD (pH=7, predicted)3.09
- Solubility (experiment)Poorly soluble
- LogS (predicted, ACD/Labs)(ph=7)-5.93
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors0
- No.of HBond Acceptors3
- No.of Rotatable Bonds0
- TPSA43.37
- StatusFDA approved
- AdministrationN/A
- PharmacologyA synthetic progestin that is an analog to spironolactone
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability76.0
- Protein binding97.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic, minor (CYP3A4-mediated)
- Half life30 h
- ExcretionRenal and fecal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe following are adverse events reported with ANGELIQ (Drospirenone/Ethynyl Estradiol combination) occurring in >10% of subjects: abdominal pain, upper respiratory infection, breast pain.
- LD50 (rat)N/A
- LD50 (mouse)N/A